There is increasing concern among patients and health care providers about the associations between PPI use and a multitude of potential adverse outcomes. Therefore, clinicians need to have a rational approach both to identifying PPI users who may not have an ongoing indication for their use and on how to encourage discontinuation of unnecessary PPI use. In this paper, we will provide a detailed review of the specific indications where the benefits of ongoing PPI use is of questionable value and will review the evidence on how to maximize the likelihood of being able to successfully discontinue PPI use while minimizing symptom recurrence.
Department of Internal Medicine, Rady School of Medicine, University of Manitoba, Winnipeg, MB, Canada
L.E.T. has received investigator-initiated funding from Janssen Canada, and served on advisory boards for AbbVie Canada, Takeda Canada, Merck Canada, Janssen Canada, Pfizer Canada, and Mallinckrodt USA. The remaining authors declare that they have nothing to disclose.
Address correspondence to: Laura E. Targownik, MD, MSHS, FRCPC, 805G-715 McDermot Avenue, Winnipeg, MB, Canada R3E 3P4 (e-mail: email@example.com).